How Many Women Have HPV: Prevalence and Lifetime Risk

Roughly 85 percent of women will acquire at least one human papillomavirus infection during their lifetime, according to modeling of U.S. sexual-behavior and epidemiological data. That estimate, which puts the average lifetime probability at about 84.6 percent under base-case assumptions, ranges from around 54 percent to 95 percent depending on sexual-activity patterns and other variables.¹ HPV is, by a wide margin, the most common sexually transmitted infection worldwide. Yet most women who contract it will never know they had it, because the immune system clears the virus before it causes any noticeable problem.

Lifetime Risk Versus What a Screening Test Shows

The distinction between “how many women will ever get HPV” and “how many have it right now” is critical. Lifetime risk is cumulative: it adds up every exposure a woman faces from her first sexual contact onward. In certain high-risk adolescent populations, cumulative prevalence rates reach as high as 82 percent before women even leave their twenties.² Point-in-time prevalence, by contrast, captures only the women who are currently infected when they happen to get tested. Because most HPV infections clear within a year or two, point-in-time surveys tend to show much lower numbers than lifetime estimates would suggest.

Blood-based antibody testing offers a window into past exposure that swab-based DNA tests miss. In one study of mid-adult women, about 68 percent were seropositive for at least one of 13 high-risk HPV types, while only 15 percent still carried detectable viral DNA. Combining both measures, roughly 71 percent showed evidence of current or past high-risk HPV infection.³ Similarly, in a study of women in Puerto Rico, antibodies against HPV types 6, 11, 16, and 18 were found in over 40 percent of participants regardless of whether they had a current genital infection, underscoring how much past exposure a simple DNA test fails to capture.⁴

How Prevalence Changes with Age

HPV prevalence in women does not follow a simple downward slope from youth to old age. Across many populations, it follows a bimodal curve: a pronounced first peak in women in their mid-twenties, a dip through middle age, and a smaller second peak in women in their fifties or later. In an unvaccinated Brazilian screening population, high-risk HPV prevalence peaked at about 26 percent in women aged 25 to 26, then declined steadily, with a second, smaller peak of roughly 9 percent appearing between ages 55 and 59.⁵ A similar two-peak pattern has been documented in Chinese populations.⁶

The first peak is straightforward: younger women are more likely to have recent new sexual partners, and their immune systems haven’t yet built up the antibody responses that partially protect against reinfection. The second peak is less well understood. It could reflect new infections acquired later in life, reactivation of latent virus that the immune system had been keeping in check, or hormonal changes around menopause that shift cervical susceptibility. A large systematic review found that the dip during middle age was consistent across regions, with prevalence among women aged 35 to 50 hovering around 15 to 20 percent depending on geography, but that trends in older women were inconsistent: some populations showed a clear late-life rise, while others showed a continued plateau or decline.⁷

Most Infections Clear, But Not All

The reason HPV prevalence figures sound so alarming while cervical cancer remains relatively rare is that the human immune system handles most infections before they do lasting damage. Among women who test positive for high-risk HPV, more than half clear the virus within about seven and a half months. Women with lower viral loads clear the infection faster than those with higher loads.⁸ In the same cohort, progression to high-grade cervical lesions occurred only in women with persistent infection. Women whose infections were transient, even if they had abnormal Pap results at the time, did not develop serious cervical disease during follow-up.

What determines whether an infection sticks around? Several independent risk factors for persistent high-risk HPV infection have been identified. Being 50 or older, carrying multiple HPV types at once, having a high viral load, reproductive tract inflammation, and thyroid dysfunction all substantially raise the odds.⁹ In a separate population-based study, a history of genital warts, current use of oral contraceptives, and use of systemic glucocorticoids were each linked to increased persistence risk, with glucocorticoid use roughly doubling the odds. The researchers interpreted these findings as signs that a dampened immune response to the virus plays a key role in whether it lingers.¹⁰

How Vaccination Is Reshaping HPV Prevalence

HPV vaccines have been available since 2006, and the population-level effects are now clearly visible. A large meta-analysis of real-world data found that after five to eight years of vaccination programs, the prevalence of HPV types 16 and 18 dropped by about 83 percent among girls aged 13 to 19 and by about 66 percent among women aged 20 to 24. Anogenital wart diagnoses fell by roughly two-thirds among teenage girls and by about half among women in their early twenties. Even boys and young men, many of whom were not vaccinated themselves in early programs, saw significant drops in wart diagnoses, reflecting herd protection.¹¹

Transmission-dynamic models suggest this herd effect will grow over time. With 80 percent vaccination coverage in girls alone, the prevalence of HPV 16 among women is predicted to drop by 93 percent after 70 years of sustained vaccination. Even at a modest 40 percent coverage, girls-only programs are expected to reduce HPV 16 prevalence in women by more than half, with even larger proportional declines for HPV types 18, 6, and 11.¹² These projections are part of why global health authorities view HPV vaccination as a genuine path toward cervical cancer elimination.

Women Living with HIV Face a Different Equation

For women with HIV, the numbers shift substantially. A systematic review and meta-analysis found that HIV-positive women had roughly 2.6 times the risk of acquiring HPV compared to HIV-negative women, along with significantly lower rates of clearing the virus once infected.¹³ The combination of easier acquisition and slower clearance means more persistent infections, more co-infections with multiple types, and a higher burden of precancerous cervical changes.¹⁴ In one study of HIV-positive women at referral centers in northeastern Brazil, nearly half tested positive for HPV, and 59 percent of those positive samples included high-risk types capable of causing cancer.¹⁵

This overlap matters especially in low- and middle-income countries, where both HIV and HPV are more common and screening infrastructure is thinner. Somewhere between 84 and 90 percent of global cervical cancer deaths occur in these settings.¹⁶ The intersection of limited access to vaccination, lower screening rates, and higher HIV prevalence creates a compounding effect that drives cervical cancer disparities worldwide.

HPV Beyond the Cervix

Cervical infection gets the most attention, but HPV can infect other anatomical sites. In women referred for colposcopy due to abnormal cervical findings, anal HPV detection rates were strikingly high. One study found high-risk HPV DNA in about 55 percent of cervical samples and 54 percent of anal samples among the same women, while oral HPV was rare, appearing in only about 2.5 percent.¹⁷ A similar pattern emerged in a case-control study comparing women with severe cervical lesions to those without: cervical and anal HPV rates were significantly higher in the high-risk group, but oral HPV prevalence was low in both groups and not significantly different between them.¹⁸

The practical takeaway is that anal HPV in women is far more common than most people realize, particularly among women who already have cervical HPV. Oral HPV, by contrast, remains uncommon. This does not mean oral HPV-related disease is unimportant — it drives a growing share of oropharyngeal cancers, especially in men — but in terms of sheer prevalence among women, the cervix and anal canal are where the virus concentrates.

How Easily HPV Passes Between Partners

HPV spreads efficiently between sexual partners. In a study tracking heterosexual couples at short intervals, concordance for at least one HPV type between partners’ genital sites ranged from 64 to 95 percent, with the highest rates seen 24 hours after intercourse.¹⁹ A Bayesian reanalysis of a Canadian cohort estimated that the median genital transmission rate for a given HPV type from a positive to a negative partner was about 4.2 per 100 person-months. Interestingly, transmission from women to men was somewhat faster than from men to women — about 5.6 versus 3.5 per 100 person-months.²⁰

These rates help explain why lifetime prevalence is so high: even a small number of sexual partners over a lifetime creates substantial cumulative exposure. Condoms reduce but do not eliminate transmission because HPV infects skin-to-skin contact areas that condoms may not cover. This is one reason why vaccination before exposure is so much more effective than behavioral measures alone at reducing population-level prevalence.

HPV During Pregnancy and Neonatal Transmission

Pregnancy doesn’t protect against HPV, and prevalence among pregnant women is substantial. In a large prospective study, about 40 percent of pregnant women tested positive for HPV at recruitment. Among those who were positive, roughly two-thirds harbored at least one high-risk genotype, and 45 percent were co-infected with multiple types.²¹ HPV was detected in about 11 percent of placentas overall, although only about 4 percent of biopsies taken from the fetal side of the placenta were positive. Neonatal HPV detection at birth or three months of age was around 7 percent, most commonly in the conjunctiva and mouth. Reassuringly, all HPV detected in newborns at birth had cleared by six months of age.

Vertical transmission from mother to child is possible through multiple routes, including passage through the birth canal and, less commonly, across the placenta.²² For most infants, this exposure appears to be transient and clinically meaningless. Rare exceptions exist, such as recurrent respiratory papillomatosis in children, which is linked to perinatal exposure to HPV types 6 and 11, but these cases are uncommon.

Self-Collection Screening

One of the barriers to understanding how many women carry HPV at any given time is that many women don’t get screened. Self-collection kits, which let women take a vaginal swab at home, are gaining ground as a way to reach underscreened populations. A systematic review of 38 studies found that over 94 percent reported self-collected specimens had accuracy comparable to clinician-collected samples, with no significant difference in HPV detection rates.²³ A 2025 clinical trial of an at-home vaginal self-collection method reported 95.2 percent agreement with clinician-collected samples for detecting high-risk HPV, and the test caught 95.8 percent of high-grade cervical lesions, matching clinician collection exactly.²⁴

In African settings, where access to clinician-led screening is more limited, a meta-analysis found that self-sampling achieved sensitivities close to 80 percent and specificities close to 90 percent for detecting high-risk HPV.²⁵ Self-collection is unlikely to fully replace clinical examination, but it could dramatically improve screening coverage in communities where women face logistical, financial, or cultural barriers to clinic-based care.

The Psychological Weight of a Positive Result

Given how common HPV is, you might expect a positive test result to feel routine. It rarely does. Qualitative research with women who tested positive for HPV during cervical screening found widespread anxiety, feelings of stigma, and worry about sexual relationships. Many women were reluctant to disclose their result to partners or others.²⁶ A meta-analysis confirmed this pattern quantitatively: women who tested HPV-positive showed significantly higher short-term anxiety than those with normal results, and the effect held regardless of whether their Pap smear was normal or abnormal.²⁷

The anxiety typically fades over time, but psychological distress can linger, particularly in women whose cytology is also abnormal. In a separate study of routine HPV primary screening, women who tested HPV-positive with normal cytology still had elevated anxiety compared to HPV-negative women, even though their actual cancer risk at that moment was very low.²⁸ This mismatch between actual risk and perceived danger is one of the harder aspects of widespread HPV screening: the test correctly identifies a common infection, but the cultural association between STIs and shame amplifies its psychological impact well beyond what the clinical picture warrants.

The Cost of Testing More Women

Adding HPV testing to cervical cancer screening catches more precancerous changes, but it also generates far more follow-up procedures. A modeling study estimated that for a cohort of one million women, biennial Pap tests from age 20 onward would lead to about 2.7 million colposcopies, roughly 1.4 million of which would turn out to be false positives. Adding HPV testing to those Pap smears pushed the colposcopy count to 4.7 million, with 3.2 million false positives.²⁹ The additional colposcopies come largely from detecting HPV infections that would have cleared on their own. Health systems have to weigh this carefully: the benefit of catching rare persistent infections earlier has to be balanced against the anxiety, discomfort, and cost of investigating millions of transient ones.

HPV Has Been with Humans Since Before Recorded History

One reason HPV is so staggeringly common is that it has been evolving alongside humans for hundreds of thousands of years. Genetic analyses of HPV-16 variants from four continents revealed two major branches, African and Eurasian, suggesting the virus diverged when early human populations separated and then spread in parallel as humans migrated across the globe.³⁰ A similar pattern holds for HPV-18, whose variants map onto major human ethnic groups, with the greatest genetic diversity found in African populations, consistent with Africa being the origin point for both the virus and its host species.³¹ HPV is not some recent invader; it has been a passenger in the human story for as long as there have been humans to infect. That ancient coevolution partly explains why the virus is so exquisitely adapted to evade immune detection and why, in most cases, the relationship between virus and host reaches a quiet truce that never leads to disease.